Achillion Falls as Liver Results Delay Hepatitis Drug Trial
This article is for subscribers only.
Achillion Pharmaceuticals Inc. fell the most in six years after a trial of one of its experimental hepatitis C drugs was delayed because of abnormal liver results.
Achillion declined 25 percent to $6.26 at the close in New York, its biggest one-day loss since February 2007.